The role of circulating tumor DNA (ctDNA) in urothelial cancers DOI Creative Commons
Jeanny B. Aragon‐Ching

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6

Published: May 19, 2025

The role of circulating tumor DNA (ctDNA) in urothelial cancers is a rapidly evolving area research. Urothelial cancer the most common subtype bladder cancer, and biomarkers that predict response or prognosticate outcomes have been long sought after. Tumor-informed ctDNA assays utilized several other increasingly used both muscle invasive (MIBC) metastatic (mUC) to inform treatment decision-making. While universal consensus on testing has not fully defined discussed herein, understanding its benefits limitations important help guide practical application clinic.

Language: Английский

Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment DOI Open Access
Giovanni Crisafulli

Genes, Journal Year: 2025, Volume and Issue: 16(1), P. 71 - 71

Published: Jan. 9, 2025

This review provides a comprehensive overview of the evolving role minimal residual disease (MRD) for patients with Colon Cancer (CC). Currently, standard care non-metastatic CC is adjuvant chemotherapy (ACT) all stage III and high-risk II following surgical intervention. Despite 5-20% improvement in long-term survival outcomes, this approach also results significant proportion receiving ACT without any therapeutic benefit being unnecessarily exposed to risks secondary side effects. underscores an unmet clinical need more precise stratification distinguish who necessitate from those can be treated surgery alone. By employing liquid biopsy, it possible discern MRD enabling categorization as MRD-positive or MRD-negative, potentially revolutionizing management ACT. aimed examine heterogeneity methodologies currently available detection, encompassing state-of-the-art technologies, their respective advantages, limitations, technological challenges multi-omic approaches that utilized enhance assay performance. Furthermore, discussion was held regarding trials employ focusing on assays used. These differences methodology, target selection, performance risk producing inconsistent may not solely reflect biological/clinical but consequence preferential use particular products studies conducted different countries. Standardization harmonization will crucial ensure revolution delivers reliable clinically actionable outcomes patients.

Language: Английский

Citations

1
Breaking up clusters of circulating tumour cells to halt cancer spread DOI
Daniel J. Smit, Klaus Pantel

Nature, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Language: Английский

Citations

1
Liquid biopsy in head and neck cancer patients: blood, saliva or both? DOI Creative Commons
Valentina De Pascale, Federica Ganci, Fabrizio Leone

et al.

Precision Clinical Medicine, Journal Year: 2025, Volume and Issue: 8(1)

Published: Jan. 7, 2025

Language: Английский

Citations

0
Recent advances in DNA nanotechnology for cancer detection and therapy: A review DOI

Donya Esmaeilpour,

Matineh Ghomi, Ehsan Nazarzadeh Zare‬

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 142136 - 142136

Published: March 1, 2025

Language: Английский

Citations

0
Translational Advances in Oncogene and Tumor-Suppressor Gene Research DOI Open Access
Radoslav Stojchevski,

Edward Agus Sutanto,

R. Sutanto

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 1008 - 1008

Published: March 17, 2025

Cancer, characterized by the uncontrolled proliferation of cells, is one leading causes death globally, with approximately in five people developing disease their lifetime. While many driver genes were identified decades ago, and most cancers can be classified based on morphology progression, there still a significant gap knowledge about genetic aberrations nuclear DNA damage. The study two critical groups genes—tumor suppressors, which inhibit promote apoptosis, oncogenes, regulate survival—can help to understand genomic behind tumorigenesis, more personalized approaches diagnosis treatment. Aberration tumor undergo two-hit loss-of-function mutations, activated forms proto-oncogenes that experience one-hit gain-of-function are responsible for dysregulation key signaling pathways cell division, such as p53, Rb, Ras/Raf/ERK/MAPK, PI3K/AKT, Wnt/β-catenin. Modern breakthroughs genomics research, like next-generation sequencing, have provided efficient strategies mapping unique changes contribute heterogeneity. Novel therapeutic enabled medicine, helping address variability suppressors oncogenes. This comprehensive review examines molecular mechanisms tumor-suppressor they regulate, epigenetic modifications, heterogeneity, drug resistance drive carcinogenesis. Moreover, explores clinical application sequencing techniques, multiomics, diagnostic procedures, pharmacogenomics, treatment prevention options, discussing future directions emerging technologies.

Language: Английский

Citations

0
Study on the clinical application value of a new type of magnetic nanomicrospheres that can be used for circulating tumor cell sorting in lung cancer DOI
Hao Feng, Huicong Zhang,

W.J. Zhang

et al.

Materials Today Chemistry, Journal Year: 2025, Volume and Issue: 45, P. 102679 - 102679

Published: April 1, 2025

Language: Английский

Citations

0
Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives DOI Open Access
Valentino Martelli, Joana Vidal, Sílvia Salvans

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1461 - 1461

Published: April 26, 2025

Peritoneal carcinomatosis (PC) represents a challenge in the management of metastatic colorectal cancer (mCRC) because difficulties diagnosis, tumor burden assessment, and selecting optimal treatments. A critical limitation is lack robust prognostic predictive biomarkers, largely relying on serum markers (e.g., carcinoembryonic antigen) or peritoneal index (PCI) for disease extent. Circulating DNA (ctDNA)-genomic fragments shed by cells into bloodstream-is now recommended international guidelines mCRC management. Its potential extends to PC, where it may enhance diagnostic, therapeutic, follow-up strategies. However, PC from CRC (PC-CRC) associated with lower ctDNA levels detection rates compared other sites, posing its clinical utility. To address these limitations, fluid analysis has emerged as promising alternative, (ptDNA) detected at higher concentrations this anatomical space. Integrating ptDNA offer deeper understanding PC-CRC biology provide more precise tools managing complex disease. This approach revolutionize treatment paradigm PC-CRC, bringing precision medicine even subgroup patients traditionally poor outcomes. review aims evaluate prognostic, therapeutic implications highlighting current limitations future directions.

Language: Английский

Citations

0
Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances DOI Creative Commons

Thanmayi Velpula,

Buddolla Viswanath

The Journal of Liquid Biopsy, Journal Year: 2025, Volume and Issue: 8, P. 100297 - 100297

Published: April 29, 2025

Language: Английский

Citations

0
Prediction of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy by Collagen Models Using Multiomic Profiles DOI Creative Commons

Maria Frantzi,

Piotr Tymoszuk, Stefan Salcher

et al.

European Urology Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

The interplay between prostate cancer and the tumor microenvironment is well documented of primary importance in disease evolution. Herein, we investigated prognostic value tissue urinary collagen-related molecular signatures predicting biochemical recurrence (BCR) after radical prostatectomy (RP). A comprehensive analysis 55 features was conducted using transcriptomic datasets (n = 1393), with further validation at proteomic level 69). Additionally, a distinct cohort 73) underwent urine-based peptidomic analysis, culminating urine-derived model. Independent significance assessed Cox proportional hazards modeling, while model's predictive performance benchmarked against established clinical metrics. An expression transcripts identified 11 significantly associated BCR (C-index: 0.55-0.72, p < 0.002). Multivariable models incorporating these enhanced accuracy, surpassing variables 0.66-0.89, Proteomic confirmed five key collagen proteins, model 0.73, 95% confidence interval: 0.62-0.85) demonstrated strong potential, although limited by small patient numbers. collagen-based predicted overall survival significant 0.59-0.70, 0.01). Collagen-based both urine emerge as robust biomarkers for following RP.

Language: Английский

Citations

0
Biomarker in der adjuvanten und neoadjuvanten Therapie des Melanoms DOI
Julian Kött, Christoffer Gebhardt

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: May 7, 2025

Personalized treatment of melanoma is becoming increasingly more important. Biomarkers offer the possibility controlling precisely and reducing side effects. The aim this text to provide an overview current tissue-based, blood-based radiological biomarkers their clinical application in melanomas. A literature research analysis studies on adjuvant neoadjuvant melanomas were carried out relevant congress contributions additionally included. Tissue-based programmed cell death 1 ligand (PD-L1) expression, interferon gamma (IFNγ) signature, gene expression profiles (GEP) tumor mutational burden (TMB) are prognostic predictive relevance. Blood-based circulating DNA (ctDNA) sense a liquid biopsy should be emphasized as personalized biomarker for longitudinal tracking during or aftercare. Positron emission tomography computed (PET-CT) body composition enable improved assessment efficiency. There currently no data from prospective validation these biomarkers; initial NivoMela study awaited. combination terms multiparametric approaches promising but further needed broad use. These not comprehensively implemented routine centers remuneration procedures.

Language: Английский

Citations

0